GTA-182

Phase Ia (dose escalation phase) (1) Primary objective: To evaluate the safety and tolerability of GTA182 in subjects with MTAPnull/lost advanced solid tumors to determine the recommended dose (RDEs) or maximum tolerated dose (MTD) for the extension phase (if any). (2) Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 in subjects with MTAPnull/lost advanced solid tumors; To evaluate the preliminary efficacy of GTA182 in subjects with MTAPnull/lost advanced solid tumors. (3) Exploratory objective: To explore biomarkers associated with the efficacy of GTA182. Phase Ib (dose expansion phase) (1) Primary objective: To evaluate the safety and tolerability of GTA182 in subjects with MTAPnull/lost advanced solid tumors at the RDEs dose to confirm the recommended dose for Phase II (RP2D). (2) Secondary objectives: To evaluate the pharmacokinetic characteristics of GTA182 at RDEs doses in subjects with MTAPnull/lost advanced solid tumors; To evaluate the preliminary efficacy of GTA182 at RDEs doses in subjects with MTAPnull/lost advanced solid tumors, and to provide a basis for the recommended dose and indication selection for subsequent clinical trials. (3) Exploratory objectives: To explore biomarkers associated with the efficacy of GTA182.